solute carrier family 22 member 14Genealiases: OCTL2 · OCTL4 · ORCTL4
Q-omics provides the consensus-scored SLC22A14 profile across patient tissues and cancer cell-line models. SLC22A14 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, SLC22A14 is differentially expressed in 9, with the highest sampling consensus in KICH. Additionally, SLC22A14 RNA expression shows 10,354 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight MESO, KICH, and UVM as cancer lineages where SLC22A14 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC22A14 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC22A14 survival associations across molecular data types. SLC22A14 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC22A14 RNA expression–survival associations across cancer types. High SLC22A14 expression shows unfavorable associations in MESO, KICH, ACC, LUAD and PRAD, but favorable associations in KIRP. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for SLC22A14 RNA expression.
This table summarizes SLC22A14 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for SLC22A14. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC22A14 shows lower tumor expression in KICH and THCA and higher tumor expression in UCEC, LUSC, COAD and CHOL. The KICH box plot shows higher SLC22A14 RNA expression in normal versus tumor tissue (log2 FC = −0.197, t-test p < 0.001).
This table shows molecular features associated with SLC22A14 in patient tissues and cancer cell lines. In patient samples, SLC22A14 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC22A14 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LARGE_INTESTINE.
